UNSPSC 51123500: Antiarrythmic benzazepines

This classification denotes compounds composed of azepines bound to benzene, substances called benzazepines, that prevent or treat irregular heartbeat, disturbances of normal rhythmic heart beating, or normal operation of myocardial contraction, thus the term ANTIARRYTHMIC BENZAZEPINES.

UNSPSC 51123500 Antiarrhythmic benzazepines is a Class code covering specific cardiac medications supplied to emergency medical services and state pharmacy benefit programs. State and local governments procure these medications primarily through fire rescue departments, emergency medical services, and state health agencies for use in advanced life support protocols and pharmacy benefit management programs. The City of Tampa's Fire Rescue and the Texas Health and Human Services Commission represent the primary recent issuing bodies, with Tampa purchasing antiarrhythmic medications including diltiazem as part of a broader Advanced Life Support Medications procurement, while Texas HHS is exploring direct-to-manufacturer prescription programs that would encompass antiarrhythmic medications within a broader pharmaceutical distribution framework. Cooperative purchasing mechanisms also drive activity under this code — the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued a multi-state RFP for generic pharmaceuticals and OTC products that includes antiarrhythmic agents as part of its comprehensive pharmaceutical supply contracts serving participating state and local government facilities across multiple jurisdictions.

Recent activity clusters in Florida, Texas, and Minnesota-led multi-state purchasing. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications with a due date of April 8, 2026 and estimated contract value of $40,000, requiring vendors to supply 1,020 units of diltiazem 25mg vials with nine-month minimum expiration, firm pricing, and FOB delivery to Tampa within ten calendar days of order receipt; the solicitation included a 5 percent bid discount for Small Local Business Enterprise participation. The Texas HHS Commission issued RFI HHS0017013 on March 27, 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs that would encompass antiarrhythmic medications outside traditional PBM and GPO channels. The MMCAP RFP (solicitation S1070000015802, due March 26, 2026) sought generic pharmaceutical manufacturers including those supplying antiarrhythmics to distribute through three authorized national wholesalers to Oregon and other participating states, with contract terms beginning July 1, 2026, and evaluation weighted 75 percent on price competitiveness.